ArticleJHLT open2026
Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in post-heart transplant patients: A multi-center retrospective cohort study.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.Heart failure reviews · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite compelling mechanistic and clinical data supporting the use of sodium glucose cotransporter 2 inhibitors (SGLT2i) in heart failure, chronic kidney disease (CKD), and type 2 diabetes (T2DM), the safety and efficacy of SGLT2i in patients with prior orthotopic heart transplant (OHT) patients remain underexplored, potentially due to concerns surrounding infection risk and kidney injury. Methods: This was a retrospective cohort study of patients receiving an SGLT2i following OHT at 7 large transplant centers between July 2016 and December 2023 to assess safety and tolerability. Key outcomes of interest included hospitalization attributed to SGLT2i use, genital/urinary tract (GU) infection, and acute kidney injury (AKI), as well as discontinuation of SGLT2i. Results: Overall, 141 patients across 7 transplant centers were included in this cohort analysis. Patients had a median age of 61, and the median time from transplant was 5.3 years. Rates of hospitalization related to SGLT2i were low, occurring in 1.4% of the study population (2/141) at a rate of 0.007 events/person-year. GU infections occurred in 9.93% (14/141) of patients, and AKI within 30 days was observed in 20.59% (21/102 patients who had a complete dataset available for analysis). At the end of the observation period, 68.1% of patients remained on an SGLT2i, and 31.9% had discontinued their SGLT2i: 15.6% of patients discontinued their SGLT2i for medical reasons, most commonly AKI or GU infection. Conclusion: Our results suggest that though discontinuation of SGLT2i use was high in patients post-OHT, the overall safety profile of the drug class was reassuring, with a low observed risk of hospitalization, kidney failure, or GU infection. Future larger prospective studies are needed to more fully elucidate the impact of SGLT2i on long-term outcomes in patients following OHT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.